Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jan 16;16(1):1.
doi: 10.1186/s12981-019-0217-3.

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study

Karam Mounzer  1 , Ricky Hsu  2 , Jennifer S Fusco  3 , Laurence Brunet  4 , Cassidy E Henegar  5 , Vani Vannappagari  5 , Chris M Stainsby  6 , Mark S Shaefer  5 , Leigh Ragone  5 , Gregory P Fusco  4
Affiliations
Observational Study

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study

Karam Mounzer et al. AIDS Res Ther. .

Abstract

Background: HLA-B*57:01 screening was added to clinical care guidelines in 2008 to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B*57:01 screening and incidence of hypersensitivity reaction were assessed in a prospective clinical cohort in the United States to evaluate the effectiveness of this intervention.

Methods: We included all patients initiating an abacavir-containing regimen for the first time in the pre-HLA-B*57:01 screening period (January 1, 1999 to June 14, 2008) or the post-HLA-B*57:01 screening period (June 15, 2008 to January 1, 2016). Yearly incidence of both HLA-B*57:01 screening and physician panel-adjudicated hypersensitivity reactions were calculated and compared.

Results: Of the 9619 patients eligible for the study, 33% initiated abacavir in the pre-screening period and 67% in the post-screening period. Incidence of HLA-B*57:01 screening prior to abacavir initiation increased from 43% in 2009 to 84% in 2015. The incidence of definite or probable hypersensitivity reactions decreased from 1.3% in the pre-screening period to 0.8% in 2009 and further to 0.2% in 2015 in the post-screening period.

Conclusions: Frequency of HLA-B*57:01 screening increased steadily since its first inclusion in treatment guidelines in the United States. This increase in screening was accompanied by a decreasing incidence of definite or probable hypersensitivity reactions over the same period. However, a considerable proportion of patients initiating abacavir were not screened, representing a failed opportunity to prevent hypersensitivity reactions. Where HLA-B*57:01 screening is standard of care, patients should be confirmed negative for this allele before starting abacavir treatment.

Keywords: Abacavir; Cohort; HIV; HLA-B*57:01 screening; Hypersensitivity reaction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Selection of eligible patients for analysis. 1As of July 31, 2016, 2Pre-screening period: 01 Jan 1999 to 14 June 2008, 3Post-screening period: 15 June 2008 to 31 July 2016
Fig. 2
Fig. 2
Trends in HLA-B*57:01 screening and physician-adjudicated HSR by calendar year
Fig. 3
Fig. 3
Time to definitive or probable hypersensitivity reaction within 6 weeks of abacavir initiation, by screening period
See this image and copyright information in PMC

References

    1. Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999;19(8):932–942. doi: 10.1592/phco.19.11.932.31568. - DOI - PubMed
    1. McDowell JA, Lou Y, Symonds WS, Stein DS. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44(8):2061–2067. doi: 10.1128/AAC.44.8.2061-2067.2000. - DOI - PMC - PubMed
    1. Weller S, Radomski KM, Lou Y, Stein DS. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2000;44(8):2052–2060. doi: 10.1128/AAC.44.8.2052-2060.2000. - DOI - PMC - PubMed
    1. Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1999;43(7):1708–1715. doi: 10.1128/AAC.43.7.1708. - DOI - PMC - PubMed
    1. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother. 1997;41(5):1094–1098. doi: 10.1128/AAC.41.5.1094. - DOI - PMC - PubMed

Publication types